Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)
A legfontosabb adatok
- Ki végzi
- Sanofi
- Hol
- Japán3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- NCT03816839
- U1111-1217-2758
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 10 fő vett részt
- Kezdés
- 2019. márc. 25.
- Befejezés
- 2024. dec. 26.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Amcenestrant (SAR439859)
- A regiszteradat frissítve
- 2025. július 7.
- Miért állt le
- Sponsor decision to prematurely stop the study, not linked to any safety concern.
Ki vehet részt
- Életkor
- 20 év felett
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Participants must be postmenopausal women
- Breast adenocarcinoma patients with locally advanced not amenable to radiation or surgery, inoperable and/or metastatic disease
- Either the primary or any metastatic site must be positive for estrogen receptor (ER) (>1% staining by immunohistochemistry)
- Either the primary tumor or any metastatic site must be human epidermal growth factor receptor 2 non-overexpressing
- Patients with at least 6 months of prior endocrine therapy
Ki nem vehet részt
- Significant concomitant illness that would adversely affect participation in the study
- Major surgery within 4 weeks prior to first study treatment administration
- Treatment with strong and moderate cytochrome P450 3A inhibitors/inducers
- Treatment with anticancer less than 2 weeks before first study treatment
- Prior treatment with selective estrogen receptor down (SERD)-regulator (except fulvestrant for which a washout of at least 6 weeks is required)
- Non-resolution of any prior treatment related toxicity to <Grade 2, except for alopecia; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
- Patients with known endometrial disorders, uterine bleeding or ovarian cysts
- Inadequate renal function with serum creatinine ≥1.5 x upper limit of normal (ULN)
- Liver function: aspartate aminotransferase >3 x ULN, or alanine aminotransferase >3 x ULN. Total bilirubin >1.5 x ULN
- Eastern Cooperative Oncology Group Performance Status (ECOG) ≥2
- Patients with a life expectancy less than 3 months
- Patient not suitable for participation, whatever the reason
- Inadequate hematological function
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Primary Objective:
A teljes eredeti leírásKevesebb
To assess the incidence rate of dose-limiting toxicity and to confirm the recommended dose as well as the maximum tolerated dose of SAR439859 administered as monotherapy to Japanese postmenopausal women with estrogen receptor positive and human epidermal growth factor receptor 2-negative advanced breast cancer.
Secondary Objective:
* To characterize the overall safety profile of SAR439859 administered as monotherapy. * To characterize the pharmacokinetic profile of SAR439859 administered as monotherapy. * To evaluate the antitumor activity of SAR439859 administered as monotherapy and the clinical benefit rate (complete response, partial response and stable disease ≥ 24 weeks).
A vizsgálat csoportja
- SAR439859A vizsgált kezelés
administered orally once daily or twice daily as monotherapy in fasted or fed state
Kezelés: Amcenestrant (SAR439859)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1 Study for the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy in Japanese Postmenopausal Women With Estrogen Receptor-Positive And Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (AMEERA-2)
- Publikációk
- A regiszteradat frissítve
- 2025. július 7.